USPTO Grants Patent for ACE Inhibitor and Blood Pressure-Lowering Agent

ChangeBridge: Patent Grants - Therapeutics (A61P)

Published March 24th, 2026

Detected March 24th, 2026

Summary

The USPTO has granted a patent (US12582146B2) to MARUZEN PHARMACEUTICALS CO., LTD. for an angiotensin-converting enzyme inhibitor and blood pressure-lowering agent containing a specific compound. The patent also covers beverages and food products incorporating this compound.

View original document View source feed page

What changed

The United States Patent and Trademark Office (USPTO) has granted patent US12582146B2 to MARUZEN PHARMACEUTICALS CO., LTD. for an angiotensin-converting enzyme (ACE) inhibitor and blood pressure-lowering agent. The patent claims a specific compound represented by formula (I) as the active ingredient, along with beverages and food products containing this compound. The patent was filed on September 2, 2020, and granted on March 24, 2026, with 12 claims.

This patent grant is primarily informational for the pharmaceutical and food manufacturing sectors. It does not impose new regulatory obligations or compliance deadlines on regulated entities. Compliance officers should note this as a development in intellectual property within the therapeutic area of cardiovascular agents, particularly for companies operating in the drug and functional food/beverage markets.

Source document (simplified)

← USPTO Patent Grants

Angiotensin-converting enzyme inhibitor, blood pressure-lowering agent, and beverages and food products

Grant US12582146B2 Kind: B2 Mar 24, 2026

Assignee

MARUZEN PHARMACEUTICALS CO., LTD.

Inventors

Yosuke Nishitani

Abstract

This angiotensin-converting enzyme inhibitor and this blood pressure-lowering agent contain a compound represented by formula (I) as an active ingredient. These beverages and food products for inhibiting an angiotensin-converting enzyme and these beverages and food products for lowering blood pressure are characterized by containing a compound represented by formula (I). As a result, provided are an angiotensin-converting enzyme inhibitor and blood pressure-lowering agent that have an excellent angiotensin-converting enzyme-inhibiting effect and blood pressure-lowering effect. Furthermore, provided are beverages and food products suitable for inhibition of an angiotensin-converting enzyme and lowering of blood pressure.